Evidence map›Paper›PMID 42511821›Full record

ArticleInternational journal of molecular sciences2026

Jiaying Wu, Xuwen Mao

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jiaying WuCollege of Pharmacy, Xinjiang Medical University, Urumqi 830017, China.
Xuwen MaoCollege of Pharmacy, Xinjiang Medical University, Urumqi 830017, China.

Funding

Natural Science Foundation of Youth Science and Technology Elite Talent Program, Xinjiang Medical University XYD2024Q01Research projects of universities in Xinjiang Uygur Autonomous Region XJEDU2025P054
6 · The paper itself

Abstract

Gut microbiota dysbiosis and metabolic disorders are key factors in inflammatory Bowel Disease (IBD) pathogenesis and progression. Although

Indexed as

ArtemisiaColitisGastrointestinal MicrobiomePlant ExtractsAnimalsCytokinesDextran SulfateDisease Models, AnimalIntestinal Barrier FunctionMaleMiceMice, Inbred C57BLCytokinesDextran SulfatePlant ExtractsArtemisia rupestris water extractgut microbiotainflammatory bowel diseasenon-targeted metabolomicssodium dextran sulfate-induced colitis

Identifiers

PMID42511821
PMCPMC13410416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.